{"DataElement":{"publicId":"3153626","version":"1","preferredName":"Patient Strong Cytochrome P450 3A4 Induction Medication Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator related to criteria to determine eligibility of patients for medical care programs and services based on strongly human CYP3A4 Gene inducing medication.","longName":"3153625v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3153625","version":"1","preferredName":"Patient Strong Cytochrome P450 3A4 Induction Medication Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services based on strongly human CYP3A4 Gene inducing medication.","longName":"2233604v1.0:3153623v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3153623","version":"1","preferredName":"Strong Cytochrome P450 3A4 Induction Medication Eligibility Determination","preferredDefinition":"Having strength, power, or intensity greater than average or expected.:Induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), Cytochrome P450 3A4 is a 502-amino acid 57.3-kD membrane-bound ER heme-thiolate monooxygenase. CYP3A4 is involved in an NADPH-dependent electron transport pathway and phase I oxidative metabolism of carcinogens, steroids, fatty acids, and xenobiotics, as well as bioactivation of aflatoxin B(1) to a genotoxic derivative. Activity seems a key predictor of drug responsiveness and toxicity. (from LocusLink, Swiss-Prot, OMIM, and NCI):The act of bringing about something.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"3153623v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strong","conceptCode":"C62223","definition":"Having strength, power, or intensity greater than average or expected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cytochrome P450 3A4","conceptCode":"C17573","definition":"Cytochrome P450 3A4 (503 aa, ~57 kDa) is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93B0B207-354C-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"ONEDATA","dateModified":"2010-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"93B0B207-355D-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"3153625v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"PT_STR_CYTOCHR_P450","type":"Context Short Name","context":"NRG"}],"ReferenceDocuments":[{"name":"Is the patient receiving any","type":"Preferred Question Text","description":"Is the patient receiving any Strong CYP3A4 inhibitors?","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Does the patient require the use of calcium channel blockers that are CYP3A4 inhibitors?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Is patient taking medications that are strong inhibitors or inducers of CYP3A4/5 (e.g., itroconzole, ketoconaole, clarithromycin, ritonavir, phenytoin, phenobarbital, and rifampicin) these medications cannot be changed?","url":null,"context":"CTEP"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Is patient receiving drugs that are strong inducers or inhibitors of CYP3A4?","url":null,"context":"PBTC"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Does the patient take any sensitive substrates of CYP3A4, CYP1A2, and CY2E1, and/or strong inhibitors and inducers of CYP2C9, CYP2D6, CYP2C19, and CYP3A4?","url":null,"context":"NRG"},{"name":"PBTC_Text3","type":"Alternate Question Text","description":"Has patient received drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A within 7 days prior to enrollment? (Please note that co-treatment with weak inhibitors of CYP3A is allowed).","url":null,"context":"PBTC"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Has patient received drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A within 7 days prior to registration? (Please note that co-treatment with weak inhibitors of CYP3A is allowed).","url":null,"context":"PBTC"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has the patient recieved chronic concomitant treatment with strong CYP3A4 inhibitor(s)?","url":null,"context":"Alliance"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Use of drugs metabolized by CYP2D6","url":null,"context":"NRG"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"Has patient within the last 7 days received or cannot discontinue drugs that are strong or moderate inducers or inhibitors of CYP3A4/5 including enzyme inducing anti-convulsant drugs (EIACDs)?","url":null,"context":"PBTC"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Is the patient on any drugs that are strong inducers or inhibitors of CYP3A4, CYP1A2, CYP2C19, UGT1A9, P-gp, and BCRP?","url":null,"context":"CTEP"},{"name":"PBTC_Text5","type":"Alternate Question Text","description":"Is patient receiving strong inducers of CYP3A4, strong inhibitors of CYP3A4 or CYP1A2, or CYP3A4 substrates with a narrow therapeutic index within 2 weeks of the first dose of savolitinib (3 weeks for St John's Wort)?","url":null,"context":"PBTC"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Is the patient using any strong cytochrome (CYP) 3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir)?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Chronic concomitant treatment with strong inhibitors of CYP3A4?","url":null,"context":"Alliance"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Chronic concomitant treatment with a strong CYP3A4 inhibitor?","url":null,"context":"Alliance"},{"name":"Alliance - 1","type":"Alternate Question Text","description":"Prior concomitant use of strong CYP3A4 inducers?","url":null,"context":"Alliance"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Prior strong CYP3A4 inducer treatment?","url":null,"context":"Alliance"},{"name":"Alliance text 6","type":"Alternate Question Text","description":"Has patient taken (or received) any known sensitive CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfenadine)  within the 14 days prior to receiving the first dose of AMG 232?","url":null,"context":"Alliance"},{"name":"NRG_CRF_Text_3","type":"Alternate Question Text","description":"Is the patient using known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or known moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, Fluconazole, verapamil)?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Is the patient taking any drugs that are strong inhibitors of CYP3A4 or CYP1A2?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_4","type":"Alternate Question Text","description":"Is the patient currently taking and unwilling/unable to discontinue the use of major substrates of CYP3A with a narrow therapeutic window?","url":null,"context":"NRG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"93B0B207-356F-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"TYRRELLM","dateModified":"2023-12-20","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"12.20.2023 Added AQT per request ticket CADSR0003202_mmt\r\n2022.12.21 AQT added per ticket request CADSR0001812. ak 8/11/22 added AQT for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}